Anthony Adamis, MD
Global Head of Ophthalmology, Immunology, Infectious Disease and Metabolism, Clinical Science
Dr. Adamis is best known for his co-discovery of the role of VEGF in ocular disease. He co-founded Eyetech (2000) and Jerini Ophthalmic (2007). At Eyetech, Dr. Adamis led the team that obtained FDA approval for the first anti-VEGF drug to treat neovascular AMD (2004). At Genentech, his team obtained FDA approval for the first anti-VEGF drug to treat retinal vein occlusion (2010), diabetic macular edema (2012), diabetic retinopathy (2015), and myopic choroidal neovascularization (2017). From 1991-2002, Dr. Adamis was on the full time faculty of the Harvard Medical School. He received his M.D. with Honors from the University of Chicago, his ophthalmology residency at the University of Michigan, and cornea fellowship at MEEI. His research training was in vascular biology with Dr. Judah Folkman.